Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.65 |
| ▸ | MMP8 | P22894 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.53 |
| ▸ | SLC12A5 | Q9H2X9 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MGAM | O43451 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SI | P14410 | 1/20 | 0.52 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3396536 | 0.90 | NPC1 (0.64) | MMP2MMP8KDRNPC1LMNA | |
| SCHEMBL9370671 | 0.81 | ROCK1 (0.55) | MMP2MMP8RAB9ALMNAHTT | |
| SCHEMBL28247801 | 0.81 | NPC1 (0.80) | MMP2MMP8NPC1RAB9ALMNA | |
| SCHEMBL3391968 | 0.77 | KDM4E (0.60) | LMNAKDM4EKMT2AALDH1A1CA1 | |
| SCHEMBL3393954 | 0.77 | CA1 (0.56) | NPC1RAB9ALMNAKMT2AALDH1A1 | |
| SCHEMBL9370896 | 0.77 | KMT2A (0.50) | MMP2MMP8LMNAMAPTHTT | |
| SCHEMBL9373080 | 0.77 | ROCK1 (0.51) | NPC1RAB9ALMNAMAPTHTT | |
| SCHEMBL9374133 | 0.77 | ROCK1 (0.51) | MMP2MMP8RAB9ALMNAHTT | |
| SCHEMBL9370715 | 0.77 | KCNQ1 (0.53) | NPC1RAB9ALMNAKDM4EMAPT | |
| SCHEMBL9371187 | 0.77 | FAAH (0.56) | MMP2MMP8NPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-02-04 | — | — | US | claimed |
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-02-04 | — | — | US | disclosed |
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2010-02-04 | — | — | US | disclosed |
| WO-2007137417-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029681-A1 | HETEROCYCLIC COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1B, CACNA1C, CACNA1I | MMP2 3074/4885MMP8 3028/4885KDR 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.